Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zylet vs TobraDex Ocular Tolerance and IOP Effects in Healthy Volunteers
NCT00532961Phase 4Completed
- Sponsor
- Bausch + Lomb
- Start
- Feb 2005
- Primary completion
- Apr 2005
- Modality
- Orthosteric Ligands, RNA-Targeting Small Molecules
01
Overview
Phase 4, randomised, double-blind trial of tobramycin + dexamethasone in ocular inflammation and Bacterial ocular infection (2 arms), sponsored by Bausch + Lomb. Primary endpoints: Ocular comfort and tolerability at Day 29 and Intraocular pressure at Day 29. Started Feb 2005; status: completed.
02
Drugs
tobramycin + dexamethasone
03
Conditions
ocular inflammationBacterial ocular infection
Beyond the preview
Go deeper on NCT00532961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00532961.